Former EMA head to advise NDA Group business

Thomas Lönngren joins new European regulatory and market access business

Independent consultancy the NDA Group has launched NDA Advisory Services, a regulatory and market access business to be based in London, UK that aims to cut the rising cost of new medicines and address the challenges of drug regulation and reimbursement, to ensure that new medicines can get to patients faster.

Thomas Lönngren, previously executive director of the European Medicines Agency (EMA), will take a strategic advisory role in the new business.

The organisation said NDA’s Advisory Board would be integral integral to NDA Advisory Services and will be expanded to include HTA and market access capabilities.

New specialists are to join the Advisory Board to advise pharmaceutical companies on how they can prove the value of their products to national agencies.

Lönngren will play a fundamental role in the new business, building on 30 years’ experience in the regulatory field including the last 10 years heading EMA. One of his key ambitions is to create a co-ordinated approach to Health Technology Assessment and improve market access in Europe.

‘I’ve recognised for a long time that the whole area of market access needs new ideas and a new vision,’ he said.

‘I plan to further develop my ideas surrounding International Regulatory Strategies, coupled with pushing for a joined-up approach to HTA, to enable the best medicines to reach needy patients as efficiently as possible.’

NDA has offices in Germany, Sweden and the UK.

You may also like

Regulatory

Shilpa Medicare targets US approval for extended-release Ondansetron injection for CINV

Shilpa Medicare plans to pursue US approval and licensing partners for OERIS after a Phase III study in India met all primary and secondary endpoints and showed a strong safety profile in chemotherapy-induced nausea and vomiting
Manufacturing

MedPharm completes FDA inspection of manufacturing plant in Durham

The topical drug product manufacturing facility in North Carolina successfully completed its FDA inspection for the commercial manufacture of drug products with no Form 483 issued plus an NAI classification
Manufacturing

New thermal inkjet printer expands AM Labels’ coding portfolio

M2 system delivers high resolution variable data printing at production-line speeds
Regulatory

Ascletis secures FDA IND clearance for Phase II Study of oral GLP-1 candidate in type 2 diabetes

Ascletis has received US FDA IND clearance to begin a 13-week Phase II trial of ASC30, its oral small-molecule GLP-1 receptor agonist, evaluating efficacy, safety and tolerability in people with type 2 diabetes
Regulatory

Novo Nordisk wins positive ruling for semaglutide compound patent from China’s Supreme People’s Court

The company has welcomed a decision by China’s Supreme People’s Court affirming the validity of its semaglutide compound patent, strengthening confidence for foreign drugmakers operating in the Chinese market
Regulatory

Grifols receives US FDA approval for new fibrinogen concentrate: FESILTY (fibrinogen, human-chmt)

The fibrinogen concentrate complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients
Regulatory

Hansa Biopharma submits BLA to FDA for Imlifidase in desensitisation for kidney transplantation

Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated immune response
Subscribe now